EMA Authorised: Enerzair Breezhaler (indacaterol;glycopyrronium bromide;mometasone) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Enerzair Breezhaler, a fixed-dose inhaler combining indacaterol, glycopyrronium bromide, and mometasone, for asthma under Novartis Europharm Limi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Enerzair Breezhaler

Snippet

Status: Authorised. Therapeutic area: Asthma. MAH: Novartis Europharm Limited. Decision date: 20/11/2025